2325 (2325) Fair Value & Analysis

Healthcare · Market cap HK$398M

2 2325 2325 · HK

PriceHK$0.6700

Fair ValueHK$0.1800

Upside-73.1%

Quality52/100

Watch 2325 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.1700 – HK$0.2000

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −15.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.6600 – HK$4.79 · fair‑value band HK$0.1700 – HK$0.2000 · the HK$0.6700 price screens above the HK$0.1800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2325 (2325) currently trades at HK$0.6700, while our model-based Fair Value estimate is HK$0.1800 — implying the stock looks roughly 73.1% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2325 generated revenue of HK$601M at a net margin of 0.5%. Revenue declined 13.2% year over year. It earns a return on equity of 0.3%. The balance sheet holds a net cash position of HK$894M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$601M

Revenue growth (YoY) -13.2%

Net margin 0.5%

Return on equity 0.3%

Free cash flow HK$246M FY2025

P/E ratio 68.0

More key figures

Operating margin 31.7%

EPS (TTM) HK$-0.0900

EPS growth (YoY) -82.1%

Net cash HK$894M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2325 reported revenue of HK$601M in FY2025 versus HK$1.7B in FY2021, a compound −22.8%/yr. Reported net income was HK$2.9M in FY2025, compounding −70.4%/yr from FY2021.

Revenue −22.8%/yr

FY21 HK$1.7B

FY22 HK$3.8B

FY23 HK$892M

FY24 HK$712M

FY25 HK$601M

Net income −70.4%/yr

FY21 HK$381M

FY22 HK$377M

FY23 −HK$102M

FY24 −HK$792M

FY25 HK$2.9M

Is 2325 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$472.80	$190.31	-60%
Danaher Corporation DHR	$186.64	$85.95	-54%
2359 2359	HK$152.80	HK$120.99	-21%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$556.94	$255.77	-54%
Lonza Group LZAGY	$63.74	$25.98	-59%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2325 (2325) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.1800 versus a price of HK$0.6700 — about −73% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2325?

Our model-based fair value for 2325 is HK$0.1800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.6700.

What is the quality score of 2325?

2325 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2325 (2325)?

2325 reported trailing-twelve-month revenue of about HK$601M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2325?

The net profit margin of 2325 is about 0.5%, meaning it keeps roughly 0.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.